Gland Pharma Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹1,834 Cr +23.3% YoYSee revenue, profit and what management said. You are viewing Q4 FY25.
GP

Gland Pharma Ltd

Q4 FY25Pharmaceuticals & Biotechnology

Gland Pharma Q4 FY25 earnings call: Revenue & Margins

Q4 FY25 earnings call: what management said on revenue, margins and capex.

Revenue
₹1,425Cr
−7.3% YoY
+3% QoQ
Net profit
₹187Cr
−2.6% YoY
−8.8% QoQ
Margin
24%
+1 pp YoY
−2 pp QoQ

Gland Pharma Ltd Q4 FY25 key numbers

Revenue
Key US growth drivers FY'26: improvement in Cenexi numbers, new product launches, tech transfer projects, dry powder contracts (~Rs 60-70 crores), biologics (~Rs 100 crores).

As stated in Gland Pharma Ltd's Q4 FY25 earnings call transcript · published 5 Aug 2026. Reported figures, not investment advice.

Price₹2,819
Market cap₹49.0K Cr
P/E42.8

The short version

FY'25 US volume growth: +9%, price decline: -5%; new launches contributed 6% to US revenue with a 72% gross margin. FY'26 overall growth guidance: mid-teens percentage (15%-17%), driven by US business growth, new launches, tech transfer projects, dry powder contracts, and biologics segment (~Rs 100 crores revenue expected in FY'26).

From Gland Pharma Ltd's Q4 FY25 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • FY'25 US volume growth: +9%, price decline: -5%; new launches contributed 6% to US revenue with a 72% gross margin.
  • Consolidated growth guidance for next year (FY'26): mid-teen percentage growth (~15%).
  • Key US growth drivers FY'26: improvement in Cenexi numbers, new product launches, tech transfer projects, dry powder contracts (~Rs 60-70 crores), biologics (~Rs 100 crores).
  • US volume growth notable in top products (24% volume increase in top 10 products).
  • GLP cartridge fill-and-finish market expected to expand significantly; capacity to increase to 140 million cartridges next year from 40 million.
  • ROW business expected to double over next 3-5 years via product registrations and cost efficiencies.
  • Cenexi to break even by December quarter, aiming for double-digit EBITDA margin in FY'27.

2 more points from Gland Pharma Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Gland Pharma Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Investment of about INR 120 crores planned for a new cartridge line, expected to be installed by the end of this year.
  • A ~60 million euro CAPEX over the next 2-3 years in Cenexi to increase capability and capacity, including:
  • Adding a new pre-filled syringe line at Hérouville site for better realization per unit.
  • Adding an additional vial line and lyophilization capacity in the Belgium site to boost high-value business.
  • Focus on replacing inefficient lines and adding new capacities for lyophilized (Lyo) products to meet growing demand.
  • Capacity expansion driven by supply constraints at two sites unable to cater to demand, particularly for Lyo products.

2 more points from Gland Pharma Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Gland Pharma Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

  • Cenexi's current order book is around Euro 100 million (Page 22).
  • Cenexi has capacity constraints at two sites due to inefficient lines, leading to aggressive capacity expansion (Pages 20-21).
  • The company is investing in new and more efficient lines to meet demand, particularly for lyophilized products (Page 21).
  • For GLP (glucagon-like peptide) fill and finish, 40 million cartridges capacity is mostly booked; the second line will be operational by year-end to cater to additional partnerships (Pages 22-23).

2 more points from Gland Pharma Ltd's call on order book

Create a free account to keep reading this call

Gland Pharma Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Gland Pharma Ltd Q4 FY25 results — key figures

Gland Pharma Ltd Q4 FY25 reported results vs Q4 FY24, ₹ crore
₹ CrQ4 FY25Q4 FY24YoYQ3 FY25QoQ
Revenue1,4251,537-7.3%1,384+3%
Operating profit (EBITDA)348359-3.1%360-3.3%
Operating margin24%23%+1 pp26%-2 pp
Profit before tax288298-3.4%299-3.7%
Net profit (PAT)187192-2.6%205-8.8%
EPS (₹)11.3211.68-3.1%12.42-8.9%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹1.8K Cr, net profit ₹291 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Pharmaceuticals & Biotechnology this season

  • Jubilant Pharmo (Q4 FY25)

    Q4 FY25 consolidated revenue grew 10% YoY to Rs. Key concall takeaways from Jubilant Pharmova Ltd's Q4 FY25 earnings call — and how it ranks against sector…

  • Anuh Pharma (Q4 FY25)

    For Q4 FY 2025, operating revenue was ₹198.14 crore, a 2.24% year-on-year increase from ₹193.63 crore in Q4 FY 2024 (derived from annual total revenue…

  • Themis Medicare (Q4 FY25)

    71.70 Cr, down 27% YoY from Rs. Key concall takeaways from Themis Medicare Ltd's Q4 FY25 earnings call — and how it ranks against sector peers.

  • Lincoln Pharmaceuticals (Q4 FY25)

    Revenue: $1.2 billion, representing a 5% increase year-on-year. Key concall takeaways from Lincoln Pharmaceuticals Ltd's Q4 FY25 earnings call — and how it…

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Gland Pharma Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Gland Pharma Ltd Q4 FY25 results?

FY'25 US volume growth: +9%, price decline: -5%; new launches contributed 6% to US revenue with a 72% gross margin. FY'26 overall growth guidance: mid-teens percentage (15%-17%), driven by US business growth, new launches, tech transfer projects, dry powder contracts, and biologics segment (~Rs 100 crores revenue expected in FY'26).

What is Gland Pharma Ltd share price analysis?

Gland Pharma Ltd currently shows a neutral. The stock trades at a P/E of 42.8 with a market cap of ₹48,998 Cr. Investors should review the full earnings analysis for detailed insights.

Is Gland Pharma Ltd planning capital expenditure?

Investment of about INR 120 crores planned for a new cartridge line, expected to be installed by the end of this year.

Keep Gland Pharma Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.